A Phase 2/3 interventional study of Intensive Lifestyle Intervention (ILI) and Megestrol Acetate 160 MG Oral Tablet in Atypical Endometrial Hyperplasia, Fertility Issues and Overweight and Obesity, sponsored by Xiaojun Chen. Recruiting at 1 site in China. Open to female participants aged 18 Years to 45 Years. Per ClinicalTrials.gov, last updated 2026-06-04.
Sponsored by Xiaojun Chen · Phase 2/3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies testing Megestrol Acetate in Endometrial Hyperplasia — 2 open to participants now, 3 under way, 1 of them phase 3. Megestrol Acetate · Endometrial Hyperplasia.
Among the 10 studies testing Megestrol Acetate in Endometrial Hyperplasia, this one is the 2nd largest by planned enrollment, is the only one that started in 2022, is one of 4 in phase 2/3, and was the 8th registered.
110 studies on the registry are indexed under Endometrial Hyperplasia; 38 are open to participants now.
Browse Endometrial Hyperplasia studies →2 of the 10 studies testing Megestrol Acetate in Endometrial Hyperplasia are open now, in 1 country. Recruiting first, the newest first:
Women's Hospital School Of Medicine Zhejiang University · Sites in China
Ages 18–45 · Women only
By country, each count listing its studies:
Megestrol Acetate: first FDA approval 1971 (MEGACE). What it is approved for, and how studies give it, is on its page →
Of the 21 Endometrial Hyperplasia studies recruiting now, 9 (43%) set no upper age limit and 11 (52%) stop at 75 or younger; 7 take children under 18; 3 take healthy volunteers.
This study: 18 Years to 45 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 9 · Phase 3 4
First in 2007; this study’s year is marked. 1 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 172 is above the median of 80 across 71 interventional studies indexed under Endometrial Hyperplasia.
Median enrollment 52 across the 10 interventional studies. Of the 5 that completed or were terminated, 2 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 10 has an industry lead sponsor. The 7 most frequent:
Xiaojun Chen is the lead sponsor of 9 studies on the registry; 3 are open to participants now.
Xiaojun Chen has 7 studies filed under Endometrial Hyperplasia — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 10 studies testing Megestrol Acetate in Endometrial Hyperplasia, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
To investigate the efficacy of weight management plus levonorgestrel intrauterine system (LNG-IUS) or megestrol acetate (MA) in obese patients with endometrial atypical hyperplasia (EAH) asking for conservative therapy.
Background:
High-efficacy progesterone, such as levonorgestrel intrauterine system (LNG-IUS), megestrol acetate (MA), and medroxyprogesterone acetate(MPA), is the first-line treatment for women with endometrial atypical hyperplasia (EAH) who want to preserve fertility. About 70% to 80% of those patients can achieve complete remission (CR) with a median CR time of about 6 months, but about 20% to 30% of those patients get no response or need longer time to get CR (over one year or even longer).
Overweight or obesity is an independent risk factor for fertility-sparing treatment response and pregnancy outcomes in young females with EAH or early endometrioid cancer (EEC). Evidence showed that obesity can cause lower CR rates and longer time to get CR and lower birth rates in EAH or EEC patients asking for conservative therapy. Weight management has been proved to improve metabolic disorders, ovarian functions, and pregnancy outcomes. Metformin, as a diabetes drug, has been proved to increase CR rates in EAH or EEC patients treated with MA for fertility. Weight management has raised more and more attention and has been proved to benefit metabolic and pregnancy outcomes. Based on previous research and published studies, the hypothesise is that weight management plus progestin therapy may raise CR rates and pregnancy outcomes in young female EAH patients asking for fertility conservation.
Enhanced lifestyle management (diet control, exercise, and daily behavioral guidance) may improve metabolic conditions, increase CR rates and pregnancy outcomes in obese EAH patients who want to preserve fertility. Till now, no similar studies were found, so this study is designed to explore the efficacy of weight control in EAH fertility-sparing patients to provide new evidence for improving conservative treatment.
Objective:
To investigate whether weight management plus LNG-IUS/MA can improve the efficacy of preserving fertility in obese EAH women who want fertility conservation.
Design:
This study is designed according to Simon's Two-Stage Design. Based on BMI and treatment plans, four single-arms are designed. This study is prospective, open-label. EAH Patients requiring conservation treatment with BMI ≥ 24 kg/m2 will be recruited in this study and they will be divided into four arms, the first group recruits overweight (24kg/ m2≤BMI\<28kg/m2) patients treated with LNG-IUS, the second group recruits overweight (24kg/ m2≤BMI\<28kg/m2) patients treated with MA, the third group recruits obese (BMI≥28kg/m2) patients treated with LNG-IUS, and the last group recruits obese (BMI≥28kg/m2) patients treated with MA. The sample size is calculated based on Simon's Two-Stage Design and previous CR rates. All enrolled patients will receive enhanced lifestyle management to control weight and take LNG-IUS/MA for treating EAH. Hysteroscopic examination, metabolic and inflammatory indicators will be performed every 12 to16 weeks while other indexes will be evaluated every month, including weight, heart rates, blood pressure, body fat tests, and so on. For the progestin efficacy evaluation, CR is defined as the remission of EAH to proliferative or secretory endometrium; partial response (PR) is defined as regression to simple or complex hyperplasia without atypia; no response (NR) is defined as the persistence of the disease, and progressive disease (PD) is defined as disease progression in patients. Two months' maintenance treatment will be recommended for patients with CR, and participants will be followed up for 2 years.
Outcomes: Primary outcome is the CR rates of the four arms. Secondary outcomes include pregnancy rates, live birth rates, weight loss, insulin resistance, chronic inflammation indicators, time to achieve CR and recurrence rates, and so on. Safety and side events during the whole trial will be monitored in two years.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
1.18 years≤age≤45years 2. (body mass index) ≥24kg/m2 3.Consent informed and signed 4. confirmed as endometrial atypical hyperplasia. Patients with endometrial specimens obtained by endometrial , diagnostic curettage or hysteroscopy and diagnosed histologically as endometrial atypical hyperplasia. If specimens are from other hospitals, they must be counseled or reconfirmed by the Department of Pathology of the Obstetrics and Gynecology Hospital of Fudan University.
5.Have a strong desire to reproduce and ask for fertility preservation or those who insist on keeping the uterus despite no reproductive requirements.
6.Have good compliance and follow-up conditions, and patients are willing to follow up in Obstetrics and Gynecology Hospital of Fudan University in time.
Exclusion Criteria:
Notes: the last 6 criteria are only applied for patients with LNG-IUS.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
enrolled overweight (24kg/m2≤BMI\<28kg/m2) patients will receive megestrol acetate 160mg po qd plus weight management
Behavioral: Intensive Lifestyle Intervention (ILI) · Drug: Megestrol Acetate 160 MG Oral Tablet
enrolled overweight (24kg/m2≤BMI\<28kg/m2) patients will be treated with LNG-IUS plus weight management
Behavioral: Intensive Lifestyle Intervention (ILI) · Drug: Levonorgestrel-Releasing Intrauterine Contraceptive System (Mirena), 52 Mg
enrolled obese (BMI≥28kg/m2) patients will receive megestrol acetate 160mg po qd plus weight management
Behavioral: Intensive Lifestyle Intervention (ILI) · Drug: Megestrol Acetate 160 MG Oral Tablet
enrolled obese (BMI≥28kg/m2) patients will be treated with LNG-IUS plus weight management
Behavioral: Intensive Lifestyle Intervention (ILI) · Drug: Levonorgestrel-Releasing Intrauterine Contraceptive System (Mirena), 52 Mg
dietary guidance, exercise guidance, lifestyle intervention
Also known as: Weight Management
enrolled participants will take Megestrol Acetate 160mg daily
Also known as: yilizhi
enrolled patients will be treated with LNG-IUS.
Also known as: manyuele
Pathological complete response (CR) rates
The 28-week CR rates will be calculated in four arms
Time frame: From date of recruitment until the date of CR, assessed up to 28 weeks.
Pregnancy outcomes
For participants have a desire for fertility, pregnancies, births and related outcomes will be counted, and the rate of pregnancy will be counted as number of pregnancies/ number of patients trying to fertility in the following period.
Time frame: up to 2 years after complete response of the last participant
Weight change
The investigators will record body weight every month and calculate its change in kilograms.
Time frame: From date of recruitment, assessed up to 28 weeks.
Body composition change
The investigators will detect body composition with InBody machine and calculate changes of the indicated indexes.
Time frame: From date of recruitment, assessed up to 28 weeks.
Blood pressures change
Record blood pressures (systolic and diastolic pressures) every 12-16 weeks and count the change during the trial.
Time frame: From date of recruitment, assessed up to 28 weeks.
Heart rates change
Record heart rates (beats per minute) every 12-16 weeks and count the change.
Time frame: From date of recruitment, assessed up to 28 weeks.
Blood glucose change
Assess fasting glucose levels each 3 to 4 months and calculate changes in mmol/L.
Time frame: From date of recruitment, assessed up to 28 weeks.
Blood lipids change
Assess blood lipids levels each 3 to 4 months and calculate changes during the trial.
Time frame: From date of recruitment, assessed up to 28 weeks.
Insulin resistance change
Test fasting insulin levels each 3 to 4 months, and count HOMA-IR index (Homeostatic Model Assessment for Insulin Resistance) with fasting insulin and fasting glucose as follow: Insulin (pmol/L)\*glucose (mmol/L)/22.5, and compare the HOMA-IR change during the treatment.
Time frame: Baseline,3months and 6months after enrolled.
Ovarian reserve function
Detect serum Anti-Mullerian Hormone (AMH) each 3 or 4 months and calculate its change.
Time frame: From date of recruitment, assessed up to 28 weeks.
Quality of life change
Collect the questionnaire SF-36 and count scores change through conservative treatment.
Time frame: From date of recruitment, assessed up to 28 weeks.
Impact of Weight on Quality of Life
Collect questionnaire IWQOL- LITE and count scores change through conservative treatment.
Time frame: From date of recruitment, assessed up to 28 weeks.
Physical activities change
Collect physical activities questionnaire(IPAQ) and compare scores changes through conservative treatment.
Time frame: From date of recruitment, assessed up to 28 weeks.
Chronic inflammatory index (TNF-α) change
The investigators will detect the levels of TNF-α (fmol/ml) in serum and calculate changes through the whole treatment period.
Time frame: baseline, 3 months and 6 months after treatment.
Chronic inflammatory index (IL-1) change
The investigators will detect serum index IL-1 in U/ml and calculate changes through the whole treatment period.
Time frame: baseline, 3 months and 6 months after treatment.
Chronic inflammatory index (IL-6) change
The investigators will detect serum index IL-6 in U/ml and calculate changes through the whole treatment period.
Time frame: baseline, 3 months and 6 months after treatment.
Time of pathological complete response (CR)
Time of histologic regression from EAH to proliferative or secretory endometrium
Time frame: From date of recruitment until the date of CR, assessed up to 2 years.
Incidence of adverse events
Adverse events related with MA, LNG-IUS and weight control. Number of participants with treatment-related adverse events as assessed by CTCAE v5.0 will be recorded, as well as incidence of adverse events.
Time frame: From date of recruitment until the date of CR, assessed up to 2 years.
Relapse rates
All enrolled patients will be followed up for 2 years. During the following-up period, if patients recur after complete regression, they will be counted and the number of recurrence will be divided by number of patients followed up, then the investigators can get the relapse rates.
Time frame: up to 2 years after the treatment for each patient
Plan to share: No
No publications or documents are linked to this record.
Ran from Jun 2022 to primary completion in Feb 2026, 44 months.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Megestrol Acetate · Levonorgestrel
Xiaojun Chen